HK1020962A1 - Substituted cyclic amine metalloprotease inhibitors - Google Patents

Substituted cyclic amine metalloprotease inhibitors

Info

Publication number
HK1020962A1
HK1020962A1 HK00100036A HK00100036A HK1020962A1 HK 1020962 A1 HK1020962 A1 HK 1020962A1 HK 00100036 A HK00100036 A HK 00100036A HK 00100036 A HK00100036 A HK 00100036A HK 1020962 A1 HK1020962 A1 HK 1020962A1
Authority
HK
Hong Kong
Prior art keywords
cyclic amine
substituted cyclic
metalloprotease inhibitors
compounds
pharmaceutical compositions
Prior art date
Application number
HK00100036A
Other languages
English (en)
Inventor
Michael George Natchus
Biswanath De
Stanislaw Pikul
Neil Gregory Almstead
Roger Gunnard Bookland
Yetunde Olabisi Taiwo
Menyan Cheng
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of HK1020962A1 publication Critical patent/HK1020962A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Confectionery (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
HK00100036A 1996-08-28 2000-01-04 Substituted cyclic amine metalloprotease inhibitors HK1020962A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2484296P 1996-08-28 1996-08-28
PCT/US1997/014555 WO1998008815A1 (en) 1996-08-28 1997-08-22 Substituted cyclic amine metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
HK1020962A1 true HK1020962A1 (en) 2000-05-26

Family

ID=21822685

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00100036A HK1020962A1 (en) 1996-08-28 2000-01-04 Substituted cyclic amine metalloprotease inhibitors

Country Status (30)

Country Link
US (6) US6417219B1 (ja)
EP (1) EP0927161B1 (ja)
JP (2) JP3541043B2 (ja)
KR (1) KR100323272B1 (ja)
CN (1) CN1232451A (ja)
AT (1) ATE226193T1 (ja)
AU (1) AU741893B2 (ja)
BR (1) BR9713465A (ja)
CA (1) CA2263928A1 (ja)
CO (1) CO4900036A1 (ja)
CZ (1) CZ63199A3 (ja)
DE (1) DE69716449T2 (ja)
DK (1) DK0927161T3 (ja)
ES (1) ES2201318T3 (ja)
HK (1) HK1020962A1 (ja)
HU (1) HUP0000478A3 (ja)
ID (1) ID18143A (ja)
IL (1) IL128666A (ja)
MY (1) MY116959A (ja)
NO (1) NO315371B1 (ja)
NZ (1) NZ334256A (ja)
PE (1) PE109098A1 (ja)
PL (1) PL331802A1 (ja)
PT (1) PT927161E (ja)
RU (1) RU2221782C2 (ja)
SK (1) SK25099A3 (ja)
TR (1) TR199900431T2 (ja)
TW (1) TWI232218B (ja)
WO (1) WO1998008815A1 (ja)
ZA (1) ZA977698B (ja)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
SI0874830T1 (en) * 1995-12-08 2003-08-31 Agouron Pharmaceuticals, Inc. A metalloproteinase inhibitor, a pharmaceutical composition containing it and the pharmaceutical use and method useful for the preparation thereof
US20020128476A1 (en) * 1996-08-08 2002-09-12 Smithkline Beecham Corporation Inhibitors of cysteine protease
BR9713465A (pt) * 1996-08-28 2000-03-28 Procter & Gamble Inibidores metalotprotease de amina cìclica sibstituìda
US6872742B2 (en) * 1996-08-28 2005-03-29 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
WO1999006340A2 (en) 1997-07-31 1999-02-11 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
US6130220A (en) * 1997-10-16 2000-10-10 Syntex (Usa) Inc. Sulfamide-metalloprotease inhibitors
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
SK11692000A3 (sk) 1998-02-04 2001-02-12 Novartis Ag Sulfonylaminoderiváty, ktoré inhibujú metaloproteinázy degradujúce matricu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
BR9910678A (pt) * 1998-05-14 2001-10-02 Du Pont Pharm Co Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
JP2002525305A (ja) * 1998-09-30 2002-08-13 ザ、プロクター、エンド、ギャンブル、カンパニー スルホンアミドを用いた脱毛治療の方法
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
AR035313A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
PL350452A1 (en) 1999-03-03 2002-12-16 Procter & Gamble Dihetero-substituted metalloprotease inhibitors
HUP0202199A2 (en) 1999-03-03 2002-10-28 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
AU3196100A (en) * 1999-03-26 2000-10-16 Shionogi & Co., Ltd. Heterocyclic sulfonamide derivatives
WO2001010838A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent compounds
WO2001010837A1 (en) * 1999-08-05 2001-02-15 The Procter & Gamble Company Multivalent sulfonamides
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
US6143776A (en) * 2000-02-02 2000-11-07 Sunesis Pharmaceuticals, Inc. Tosylproline analogs as thymidylate synthase inhibitors
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
PL360678A1 (en) 2000-03-17 2004-09-20 Bristol-Myers Squibb Pharma Company Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
EP1138680A1 (en) 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
KR100372757B1 (ko) * 2000-04-07 2003-02-17 삼성전자주식회사 메트릭스 메탈로프로테이나제의 저해제로서의 설폰아미드유도체
CN1536989A (zh) 2000-06-30 2004-10-13 促进全身健康
US8283135B2 (en) 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
JP3983663B2 (ja) * 2000-07-19 2007-09-26 エフ．ホフマン−ラ ロシュ アーゲー メタロプロテアーゼインヒビターとしてのピロリジン誘導体
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
CN1620433A (zh) * 2000-07-19 2005-05-25 霍夫曼-拉罗奇有限公司 作为内皮肽转化酶抑制剂的吡咯烷衍生物
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4825375B2 (ja) 2001-08-28 2011-11-30 株式会社 資生堂 ジチアゾール化合物及びマトリックスメタロプロテアーゼ活性阻害剤、皮膚外用剤
EP1440057A1 (en) 2001-11-01 2004-07-28 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
EP1452527B1 (en) 2001-11-13 2009-03-04 Shiseido Co., Ltd. Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation
WO2003059265A2 (en) * 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
WO2005021489A2 (en) 2002-12-23 2005-03-10 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
EP1613269B1 (en) 2003-04-04 2015-02-25 Incyte Corporation Compositions, methods and kits relating to her-2 cleavage
WO2004112796A1 (en) * 2003-06-20 2004-12-29 Alcon, Inc. Treatment of amd with combination of ingredients
CN1294120C (zh) * 2003-10-21 2007-01-10 山东大学 吡咯烷类基质金属蛋白酶抑制剂及其应用
DE102004031620A1 (de) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-Trifluormethoxyphenoxybenzol-4`-sulfonsäuren, Verfahren zu ihrer Herstellung und Verwendung in Arzneimitteln
ES2402362T3 (es) 2004-09-30 2013-05-03 Takeda Pharmaceutical Company Limited Inhibidores de la bomba de protones
BRPI0607156A2 (pt) * 2005-02-18 2009-08-11 Innodia Inc composto, composição farmacêutica, uso do composto, kit farmacêutico, método para estimular a absorção de glicose por células de músculo e/ou célula de adipócito e método para estimular a secreção pancreática
PE20110009A1 (es) 2005-08-30 2011-01-31 Takeda Pharmaceutical Derivados de pirrol como inhibidores de la secrecion acida
ES2443242T3 (es) 2005-12-23 2014-02-18 Zealand Pharma A/S Compuestos modificados miméticos de lisina
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
ES2330291B1 (es) 2008-02-29 2010-10-18 Lipotec Sa Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas.
US8969387B2 (en) 2008-08-27 2015-03-03 Takeda Pharmaceutical Company Limited Pyrrole compounds
ES2349972B1 (es) 2009-02-16 2011-11-24 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosméticas o farmacéuticas.
JP2014528963A (ja) * 2011-10-04 2014-10-30 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） 新規のアポトーシス誘導化合物
TW201825458A (zh) 2016-09-20 2018-07-16 英商葛蘭素史克智慧財產（第二）有限公司 Ｔｒｐｖ４拮抗劑
WO2018055527A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
CA3036933A1 (en) 2016-09-20 2018-03-29 Glaxosmithkline Intellectual Property (No.2) Limited Trpv4 antagonists
EP3618847B1 (en) 2017-05-05 2021-04-07 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954158A (en) * 1983-08-16 1990-09-04 University Of Georgia Research Foundation, Inc. 2,3-methanoproline
ZA877471B (en) * 1986-10-08 1988-04-05 Bristol-Myers Company 1-tertiary-alkyl-substituted naphthyridine-and quinoline-carboxylic acid antibacterial agents
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5861510A (en) * 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
KR100266467B1 (ko) * 1995-09-27 2000-10-02 우에노 도시오 설폰아미드 유도체
SI0874830T1 (en) * 1995-12-08 2003-08-31 Agouron Pharmaceuticals, Inc. A metalloproteinase inhibitor, a pharmaceutical composition containing it and the pharmaceutical use and method useful for the preparation thereof
FR2743073B1 (fr) * 1995-12-29 1998-02-20 Fournier Ind & Sante Nouveaux composes de 1-benzenesulfonylpyrrolidine, procede de preparation et utilisation en therapeutique
FR2743562B1 (fr) * 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
BR9713465A (pt) * 1996-08-28 2000-03-28 Procter & Gamble Inibidores metalotprotease de amina cìclica sibstituìda
US6376506B1 (en) * 1997-01-23 2002-04-23 Syntex (U.S.A.) Llc Sulfamide-metalloprotease inhibitors
ZA98376B (en) * 1997-01-23 1998-07-23 Hoffmann La Roche Sulfamide-metalloprotease inhibitors
US6261775B1 (en) * 1999-04-09 2001-07-17 The Regents Of The University Of California Detection of chromosome copy number changes to distinguish melanocytic nevi from malignant melanoma

Also Published As

Publication number Publication date
CO4900036A1 (es) 2000-03-27
JP2004115531A (ja) 2004-04-15
SK25099A3 (en) 2000-02-14
PT927161E (pt) 2003-12-31
US20020072517A1 (en) 2002-06-13
KR100323272B1 (ko) 2002-02-06
IL128666A0 (en) 2000-01-31
DK0927161T3 (da) 2003-02-17
ID18143A (id) 1998-03-05
PL331802A1 (en) 1999-08-02
US20050101567A1 (en) 2005-05-12
US20050154019A1 (en) 2005-07-14
JP3541043B2 (ja) 2004-07-07
TWI232218B (en) 2005-05-11
KR20000035922A (ko) 2000-06-26
NZ334256A (en) 2000-11-24
EP0927161A1 (en) 1999-07-07
JP2000516955A (ja) 2000-12-19
CA2263928A1 (en) 1998-03-05
US20020061877A1 (en) 2002-05-23
AU4074197A (en) 1998-03-19
ZA977698B (en) 1998-02-23
ATE226193T1 (de) 2002-11-15
CN1232451A (zh) 1999-10-20
MY116959A (en) 2004-04-30
ES2201318T3 (es) 2004-03-16
US6858628B2 (en) 2005-02-22
HUP0000478A2 (hu) 2000-09-28
IL128666A (en) 2005-09-25
NO990855L (no) 1999-04-23
AU741893B2 (en) 2001-12-13
CZ63199A3 (cs) 1999-08-11
US6569855B2 (en) 2003-05-27
US6417219B1 (en) 2002-07-09
WO1998008815A1 (en) 1998-03-05
HUP0000478A3 (en) 2000-10-30
TR199900431T2 (xx) 1999-04-21
RU2221782C2 (ru) 2004-01-20
PE109098A1 (es) 1999-02-19
NO315371B1 (no) 2003-08-25
DE69716449D1 (de) 2002-11-21
NO990855D0 (no) 1999-02-23
BR9713465A (pt) 2000-03-28
US20030191163A1 (en) 2003-10-09
EP0927161B1 (en) 2002-10-16
DE69716449T2 (de) 2003-08-07

Similar Documents

Publication Publication Date Title
HK1020962A1 (en) Substituted cyclic amine metalloprotease inhibitors
CA2264254A1 (en) Phosphinic acid amides as matrix metalloprotease inhibitors
PT966465E (pt) Inibidores do enzima imfdh
AP1498A (en) Inhibitors of impdh enzyme.
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
BG104780A (en) Inhibitors of phospholipase enzymes
IL128691A0 (en) Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
ES2136037A1 (es) Inhibidores de sulfamida-metaloproteasa
NO990896L (no) Bidentate metalloproteaseinhibitorer
IL125285A0 (en) Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and pharmaceutical compositions containing the same
EA199900632A1 (ru) 2-амино-6-(2-замещенные-4-фенокси)-замещенные-пиридины
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
MY113863A (en) Method for preparing n, n' - disubstituted cyclic ureas
WO2001070720A3 (en) Carbocyclic side chain containing, n-substituted metalloprotease inhibitors
BR0014759A (pt) Inibidores de metaloprotease beta dissubstituìdos
MX9704968A (es) Inhibidores que contienen acido hidroxamico de metaloproteasas de matriz.
WO2001070682A3 (en) Carbocyclic side chain containing metalloprotease inhibitors
GEP20032923B (en) Sulphonamide Derivatives as Prodrugs of Aspartyl Protease Inhibitors, Pharmaceutical compositions containing the Same and Methods for Treatment
BG103044A (en) 7-bromo- and 7,7-dibromo-cepham and -cephem derivatives
MX9700828A (es) Analogos del acido aspartico como inhibidores de la enzima que convierte a la interleucina-1 beta.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20060822